BRCA1 is an inclusion eligibility criterion in 4 clinical trials for primary peritoneal endometrioid adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 4 clinical trials for primary peritoneal endometrioid adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].